nach oben

International Urology and Nephrology

Erschienen in:

29.01.2023 | Urology - Original Paper

Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients

verfasst von: Tengfei Gu, Jie Li, Ting Chen, Qingfeng Zhu, Jiafeng Ding

Erschienen in: International Urology and Nephrology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Circulating tumor cells (CTCs) predict survival in response to different interventions in metastatic castration-resistant prostate cancer (mCRPC) patients. This study aimed to explore the dynamic change in CTCs during abiraterone plus prednisone therapy and its optimal threshold for prognostication in mCRPC patients.

Methods

CTCs in blood samples from mCRPC patients (N = 98) at baseline and in the 2nd month after abiraterone plus prednisone treatment initiation (M2) were enumerated by using the CellSearch System.

Results

CTCs were detected in 64.8% of mCRPC patients at baseline with a median value (interquartile range) of 2.0 (0.0–4.0). Elevated CTC count was related to visceral metastasis (P = 0.003), high alkaline phosphatase (P = 0.043), and high lactate dehydrogenase (P = 0.007). Baseline CTC ≥ 1 (vs. < 1) was only associated with shortened radiographic progression-free survival (rPFS) (P = 0.043); additionally, baseline CTC ≥ 5 (vs. < 5) was linked with unfavorable rPFS (P = 0.037) and overall survival (OS) (P = 0.021). Following the therapy, CTCs were reduced at M2 (P < 0.001). Notably, CTC ≥ 1 (vs. < 1) (P = 0.002) and CTC ≥ 5 (vs. < 5) (P < 0.001) at M2 were related to shortened rPFS according to the Kaplan‒Meier curves, and they could independently estimate deteriorative rPFS in the multivariate Cox regression (P = 0.043 and P = 0.027, respectively). Similarly, CTC ≥ 1 (vs. < 1) (P = 0.022) and CTC ≥ 5 (vs. < 5) (P = 0.002) at M2 were related to shortened OS, whereas only CTC ≥ 5 (vs. < 5) could independently predict unfavorable OS (P = 0.017).

Conclusion

CTC count ≥ 5 at M2 exhibits excellent prognostic value for abiraterone plus prednisone therapy in mCRPC patients.

Nur mit Berechtigung zugänglich

Mansinho A, Macedo D, Fernandes I, Costa L (2018) Castration-resistant prostate cancer: mechanisms, targets and treatment. Adv Exp Med Biol 1096:117–133. https://doi.org/10.1007/978-3-319-99286-0_7CrossRefPubMed

Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R (2020) Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells. https://doi.org/10.3390/cells9122653CrossRefPubMedPubMedCentral

Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239–243. https://doi.org/10.1038/nature11125CrossRefPubMedPubMedCentral

Foley C, Mitsiades N (2016) Moving beyond the androgen receptor (AR): targeting AR-interacting proteins to treat prostate cancer. Horm Cancer 7(2):84–103. https://doi.org/10.1007/s12672-015-0239-9CrossRefPubMedPubMedCentral

Zhou J, Wang Y, Wu D, Wang S, Chen Z, Xiang S, Chan FL (2021) Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer. Oncogene 40(15):2625–2634. https://doi.org/10.1038/s41388-021-01737-1CrossRefPubMedPubMedCentral

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, D’Anello L, Csibi A, Kalekar R, Larimer B, Ellis L, Butler LM, Morrissey C, McGovern K, Palombella VJ, Kutok JL, Mahmood U, Bosari S, Adams J, Peluso S, Dehm SM, Plymate SR, Loda M (2019) Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proc Natl Acad Sci USA 116(2):631–640. https://doi.org/10.1073/pnas.1808834116CrossRefPubMed

Desai K, McManus JM, Sharifi N (2021) Hormonal therapy for prostate cancer. Endocr Rev 42(3):354–373. https://doi.org/10.1210/endrev/bnab002CrossRefPubMedPubMedCentral

Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS, Investigators C-A (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992. https://doi.org/10.1016/S1470-2045(12)70379-0CrossRefPubMed

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, Investigators C-A (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160. https://doi.org/10.1016/S1470-2045(14)71205-7CrossRefPubMed

10.

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS (2021) Advanced prostate cancer: AUA/ASTRO/SUO guideline PART II. J Urol 205(1):22–29. https://doi.org/10.1097/JU.0000000000001376CrossRefPubMed

11.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038. https://doi.org/10.1056/NEJMoa1315815CrossRefPubMedPubMedCentral

12.

Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J (2015) PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 67(4):795–802. https://doi.org/10.1016/j.eururo.2014.10.027CrossRefPubMedPubMedCentral

13.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D’Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS (2018) Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest 128(10):4441–4453. https://doi.org/10.1172/JCI121924CrossRefPubMedPubMedCentral

14.

Castro-Giner F, Aceto N (2020) Tracking cancer progression: from circulating tumor cells to metastasis. Genome Med 12(1):31. https://doi.org/10.1186/s13073-020-00728-3CrossRefPubMedPubMedCentral

15.

Chong W, Zhang Z, Luo R, Gu J, Lin J, Wei Q, Li B, Myers R, Lu-Yao G, Kelly WK, Wang C, Yang H (2021) Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. BMC Cancer 21(1):655. https://doi.org/10.1186/s12885-021-08405-3CrossRefPubMedPubMedCentral

16.

de Kruijff IE, Sieuwerts AM, Onstenk W, Kraan J, Smid M, Van MN, van der Vlugt-Daane M, Hoop EO, Mathijssen RHJ, Lolkema MP, de Wit R, Hamberg P, Meulenbeld HJ, Beeker A, Creemers GJ, Martens JWM, Sleijfer S (2019) Circulating tumor cell enumeration and characterization in metastatic castration-resistant prostate cancer patients treated with cabazitaxel. Cancers (Basel). https://doi.org/10.3390/cancers11081212CrossRefPubMed

17.

Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R, Scafuri L, Verde A, Bruzzese D, Iaccarino S, Costabile F, Onofrio L, Viggiani M, Palmieri A, De Placido P, Marretta AL, Pietroluongo E, Luce A, Abate M, Navaeiseddighi Z, Caputo VF, Celentano G, Longo N, Ferro M, Morelli F, Facchini G, Caraglia M, De Placido S, Buonerba C (2021) Assessment of total, PTEN(-), and AR-V7(+) circulating tumor cell count by flow cytometry in patients with metastatic castration-resistant prostate cancer receiving enzalutamide. Clin Genitourin Cancer 19(5):e286–e298. https://doi.org/10.1016/j.clgc.2021.03.021CrossRefPubMed

18.

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, Investigators C-A (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148. https://doi.org/10.1056/NEJMoa1209096CrossRefPubMed

19.

Hillig T, Horn P, Nygaard AB, Haugaard AS, Nejlund S, Brandslund I, Soletormos G (2015) In vitro detection of circulating tumor cells compared by the CytoTrack and cell search methods. Tumour Biol 36(6):4597–4601. https://doi.org/10.1007/s13277-015-3105-zCrossRefPubMed

20.

Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB Jr, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE, Investigators A (2021) Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol 22(11):1541–1559. https://doi.org/10.1016/S1470-2045(21)00402-2CrossRefPubMedPubMedCentral

21.

de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309. https://doi.org/10.1158/1078-0432.CCR-08-0872CrossRefPubMed

22.

De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, Van Kerckhove P, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff I, van Dam V, Brouwer A, van Dam PJ, Van den Eynden G, Rutten A, Sleijfer S, Vandebroek J, Van Laere S, Dirix L (2018) Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. Prostate 78(6):435–445. https://doi.org/10.1002/pros.23488CrossRefPubMed

23.

Kumar S, Park SH, Cieply B, Schupp J, Killiam E, Zhang F, Rimm DL, Frisch SM (2011) A pathway for the control of anoikis sensitivity by E-cadherin and epithelial-to-mesenchymal transition. Mol Cell Biol 31(19):4036–4051. https://doi.org/10.1128/MCB.01342-10CrossRefPubMedPubMedCentral

24.

Tinganelli W, Durante M (2020) Tumor hypoxia and circulating tumor cells. Int J Mol Sci. https://doi.org/10.3390/ijms21249592CrossRefPubMedPubMedCentral

25.

Wang G, Zhao D, Spring DJ, DePinho RA (2018) Genetics and biology of prostate cancer. Genes Dev 32(17–18):1105–1140. https://doi.org/10.1101/gad.315739.118CrossRefPubMedPubMedCentral

26.

Vimalraj S (2020) Alkaline phosphatase: structure, expression and its function in bone mineralization. Gene 754:144855. https://doi.org/10.1016/j.gene.2020.144855CrossRefPubMed

27.

Lagana G, Barreca D, Calderaro A, Bellocco E (2019) Lactate dehydrogenase inhibition: biochemical relevance and therapeutical potential. Curr Med Chem 26(18):3242–3252. https://doi.org/10.2174/0929867324666170209103444CrossRefPubMed

28.

Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y (2018) Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med 7(12):6124–6136. https://doi.org/10.1002/cam4.1820CrossRefPubMedPubMedCentral

29.

Schlack K, Seitzer K, Wustmann N, Humberg V, Grundmann N, Steinestel J, Tiedje D, Rahbar K, Krabbe LM, Bogemann M, Schrader AJ, Bernemann C (2022) Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients. Sci Rep 12(1):11846. https://doi.org/10.1038/s41598-022-16094-6CrossRefPubMedPubMedCentral

30.

Heitmeir B, Deniz M, Janni W, Rack B, Schochter F, Wiesmuller L (2022) Circulating tumor cells in breast cancer patients: a balancing act between stemness, EMT features and DNA damage responses. Cancers (Basel). https://doi.org/10.3390/cancers14040997CrossRefPubMed

31.

Lv Y, Zhang X, Chen L (2021) Suspension state regulates epithelial-to-mesenchymal transition and stemness of breast tumor cells. Biotechnol Lett 43(3):561–578. https://doi.org/10.1007/s10529-020-03074-xCrossRefPubMed

32.

Chiang SP, Cabrera RM, Segall JE (2016) Tumor cell intravasation. Am J Physiol Cell Physiol 311(1):C1–C14. https://doi.org/10.1152/ajpcell.00238.2015CrossRefPubMedPubMedCentral

33.

Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, Reid AHM, Cendon Y, Bianchini D, Llacer C, Sandhu SK, Sharp A, Rescigno P, Garces T, Pacheco MI, Flohr P, Massard C, Lopez-Casas PP, Castro E, de Bono JS, Olmos D (2021) Value of early circulating tumor cells dynamics to estimate docetaxel benefit in metastatic castration-resistant prostate cancer (mCRPC) patients. Cancers (Basel). https://doi.org/10.3390/cancers13102334CrossRefPubMed

34.

Ye Q, Ling S, Zheng S, Xu X (2019) Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer 18(1):114. https://doi.org/10.1186/s12943-019-1043-xCrossRefPubMedPubMedCentral

35.

Theil G, Lindner C, Bialek J, Fornara P (2021) Association of circulating tumor cells with inflammatory and biomarkers in the blood of patients with metastatic castration-resistant prostate cancer. Life (Basel). https://doi.org/10.3390/life11070664CrossRefPubMed

Titel: Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients
verfasst von: Tengfei Gu
Jie Li
Ting Chen
Qingfeng Zhu
Jiafeng Ding
Publikationsdatum: 29.01.2023
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 4/2023
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-023-03481-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Estimation of pulmonary artery systolic pressure in hemodialysis patients and its association with cardiorespiratory fitness and pulmonary function

The relationship between depression, anxiety, quality of life levels, and the chronic kidney disease stage in the autosomal dominant polycystic kidney disease

Efficiency of ferric carboxymaltose in non-dialysis CKD patients and its impact on kidney function: a prospective observational study

An update review on hemodynamic instability in renal replacement therapy patients

The effect of psychosocial interventions on depression, anxiety, and quality of life in hemodialysis patients: a systematic review and a meta-analysis